\
&
Contact us
\
&
Contact us
This was 4 weeks ago
LocationParis, France
The SMI2G brokerage event gathers European-wide innovators and practitioners looking for further consortium partners by presenting game-changing ideas and novel technologies addressing the challenges of Horizon Europe's Civil Security for Society 2025-2026 Work Programme (not yet published).
The SMI2G brokerage event is organised by the EARTO Working Group Security and Defence Research, the SEREN network, EOS, IMG-S, and CMINE and is supported by the Ministère de l’Enseignement Supérieur et de la Recherche and ENLET.
Every year, SMI2G hosts top-level keynote speakers, expert panel discussions, and ground-breaking pitch sessions related to the respective calls. As a result, the event offers participants significant networking opportunities, supports consortium-building efforts, and shares valuable information concerning the Horizon Europe Security Calls.
For more information and to register for this event please access the dedicated event page.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Climate, Energy, Mobility Agro-Food, Environment
Digital, Industry & Space Climate, Energy, Mobility
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
